IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class

Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.
Read the full report on Asianet Newsable
Story file
- Section
- India
- Topics
- Stock market
- First reported by
- Asianet Newsable
- Reporter
- stocktwits inc
- Published
- Friday, 9 October 2026, 12:20 am IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Asianet Newsable with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.


